Fluorescence in Situ Hybridization Study of HER-2/neu Oncogene Amplification in Prostate Cancer

Mark, Hon Fong L.; Feldman, David; Das, Sam; Kye, H; Mark, Seamus; Sun, Ci-Lin; Samy, Mangala

doi:10.1006/exmp.1999.2242

Cited by 48 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As seen in the present study, immunoreactivity for this receptor has been reported in 9% (Mark et al, 1999) up to 30% in untreated patients (20%, Osman et al, 2001;25%, Signoretti et al, 2000;29%, Xie et al, 1995;and 30%, Fossa et al, 2002). Savinainen et al (2002) did not find c-erbB-2 immunoreactivity in any of 54 specimens from untreated patients, nor in 20 lymph node metastases or 50 hormone-refractory tumours.…”

Section: Discussionsupporting

confidence: 78%

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

et al. 2004

View full text Add to dashboard Cite

Novel palliative strategies for patients with androgen-independent prostate cancer (AIPC) include targeting the epidermal growth factor receptor (EGFR) family. The aim of the present study was to investigate intrapatient changes of EGFRs during the development of AIPC. In total, 106 symptomatic AIPC patients were identified in whom prostatic biopsies (adenocarcinoma) were available both before the start of androgen deprivation (PRTR biopsy) and after the development of AIPC (AIPC biopsy). All four known subgroups of the EGFR family were determined by immunohistochemistry (IHC): c-erbB-1 (EGFR), c-erbB-2 (HER2/neu), c-erbB-3 (HER3) and c-erbB-4 (HER4). Moderate to strong membrane-specific staining was recorded semiquantitatively (o10% vs X10% ¼ IHC stained tumour cells: 'negative' vs 'positive' staining). The medical records were reviewed for clinical variables. During the development of AIPC, intrapatient changes occurred in two opposite directions for each of the four EGFRs: negativity changed to positivity, and vice versa, statistically significant only for the increase of c-erbB-1 expression (P ¼ 0.001). The c-erbB-2 expression in the AIPC biopsy was associated with a significantly shorter survival from the time of the AIPC biopsy (P ¼ 0.029). Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer. Further research is needed to understand the function of EGFRs in this malignancy.

show abstract

Section: Discussionsupporting

confidence: 78%

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The results of the present study were consistent with previous studies, in which HER2 amplification was reported in 44 and 41% of 62 and 113 Americans, respectively, using the FISH method (54,62), whereas another analysis reported no HER2 amplification (63). Furthermore, in a previous study, FFPE tissue blocks from 88 patients demonstrated a minor amplification rate of 9.3% (8/88 cases) (64). Similarly, Qi et al (53) used a FISH method and demonstrated that only 5.8% of Chinese patients with PCa had such a genetic alteration, and an investigation of 93 cancer samples showed that 6.5% had low levels of HER2 amplification, which was co-amplified with the topoisomerase (DNA) II α gene (65).…”

supporting

confidence: 92%

HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method

et al. 2016

View full text Add to dashboard Cite

Abstract. Prostate cancer (PCa) is one of the most widespread malignancies in the world. The role of the human epidermal growth factor receptor 2 (HER2) in the pathogenesis and progression of human PCa remains poorly understood. In contradiction with breast cancer, studies on HER2 overexpression and gene amplification in PCa have produced varying results, although the HER2 oncogene has been implicated in the biology of numerous tumor types, and serves as a prognostic marker and therapeutic target in breast cancer. Technical challenges are considered the main reasons for data discrepancies. Amplification of the HER2 gene has previously been reported in PCa, in which it was associated with tumor progression. The present study aimed to evaluate the prevalence and clinical significance of HER2 amplification in PCa. A total of 32 biopsy samples obtained from human prostate adenocarcinomas were evaluated by chromogenic in situ hybridization (CISH) to determine the frequency of patients with HER2 gene amplifications. High copy numbers of HER2 were detected in 19 of the prostate tumors analyzed. The results of the present study suggested that, in patients without amplification of HER2, high levels of prostate-specific antigen or a high Gleason score were not significantly correlated with a high pathologic stage. Furthermore, amplification levels of the HER2 gene were directly associated with pathologic stage in patients with PCa. Therefore, the potential use of HER2 as a prognostic factor or therapeutic target for PCa warrants further study. IntroductionProstate cancer (PCa), a common non-skin, sex-limited cancer, is the second cause of cancer-associated mortality (after lung cancer) in the USA (1,2) and the second most prevalent cancer among Iranian men (3). Worldwide, PCa is the second most commonly diagnosed cancer and, according to the International Agency for Research on Cancer's GLOBOCAN 2012 (4) database, it is the fifth leading cause of cancer-associated mortality in men. The incidence of PCa is increasing worldwide, although there is a marked variation in its incidence among different regions (5). The clinical configuration of PCa has noticeably altered over the past few years. As a localized disease, it is easily treated by radical radiation therapy or a prostatectomy; however, if the tumor becomes malignant, it transforms into a life-threatening disease (6).The progression and application of novel high-resolution technologies has enhanced the detection of genomic alterations, enabling elucidation of the complex nature and heterogeneity of PCa (7). The differentiation of PCa tumors is typically based on the serum expression levels of prostate-specific antigen (PSA), although, in certain cases, PSA levels do not accurately reflect tumor burden (8). Previous studies have identified a number of genetic, epigenetic and environmental risk factors for PCa (9-11). Among them, genetic aberrations and chromosomal changes have been suggested to serve a significant role in the development and progression of PCa (12)

show abstract

“…7,20 Over the last decade there has been continued debate as to the role of Her-2 in PC. 21,22 In clinically localized PC, HER-2 gene amplification has been reported for 0 -41% of the cases, [23][24][25][26] and the published incidence of Her-2 expression by immunohistochemistry [IHC] varies from 0 -100%. [27][28][29][30][31][32][33][34] Methodologic differences have been noted as possible explanations for this variation.…”

Section: Discussionmentioning

confidence: 99%

Independent prognostic significance of HER‐2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy

Fosså

Lilleby

Fosså

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Existing prognostic algorithms for localized prostate cancer (PC) are hampered by poor validation for endpoints other than biochemical relapse such as clinical disease progression or survival. Therefore, the prognostic relevance of Her-2 (Her-2/neu, c-erbB2) protein expression in patients undergoing curative radiotherapy (RT) was compared to widely accepted prognostic factors such as pretreatment prostate-specific antigen (PSA) levels, biopsy Gleason score and T category of the primary tumor. Biopsies from 112 homogeneously treated patients with T1-4pN0M0 PC were examined by immunohistochemistry and 37% of cases showed membrane-bound Her-2 expression in more than 10% of cancer cells. No definite membrane staining was seen in normal prostate epithelium. With 25 patients dead of PC and a median follow-up of surviving patients of 71 months (range 48 -144), the prognostic relevance of Her-2 expression was univariately associated with adverse outcome in terms of biochemical or clinical progression-free survival (B/C-PFS; p ‫؍‬ 0.04), clinical progression-free survival (C-PFS; p ‫؍‬ 0.02) and disease-specific survival (DSS; p ‫؍‬ 0.02). In multivariate analysis, Her-2 expression, T category and Gleason score were independently associated with C-PFS, whereas only Her-2 expression and Gleason score were associated with DSS. Her-2 expression and Gleason score together discriminated 2 groups of patients with 5-year DSS of 95% and 79%, respectively (p < 0.001). Pretreatment PSA levels were associated only with B/C-PFS but not with C-PFS or DSS. Together the data show for the first time that expression of Her-2 is of prognostic relevance in localized PC undergoing RT and suggest that analysis for Her-2 may improve prognostic algorithms for clinically relevant endpoints other than biochemical relapse.

show abstract

Fluorescence in Situ Hybridization Study of HER-2/neu Oncogene Amplification in Prostate Cancer

Cited by 48 publications

References 22 publications

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method

Independent prognostic significance of HER‐2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy

Contact Info

Product

Resources

About